Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 6/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | PDE5A | O76074 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.56 |
| ▸ | PDE1A | P54750 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olprinone SCHEMBL19205852 | 1.00 | PDE3A (1.00) | PDE3APDE4AHPGDBLMCYP3A4 | |
| Olprinone SCHEMBL6052374 | 0.99 | HPGD (1.00) | PDE3APDE4AHPGDBLMCYP3A4 | |
| Olprinone SCHEMBL27901698 | 0.99 | PDE3A (0.98) | PDE3APDE4AHPGDBLMCYP3A4 | |
| Olprinone SCHEMBL563912 | 0.99 | HPGD (1.00) | PDE3APDE4AHPGDBLMCYP3A4 | |
| Olprinone SCHEMBL931814 | 0.95 | PDE3A (0.90) | PDE3APDE4AHPGDBLMCYP3A4 | |
| Olprinone SCHEMBL28068934 | 0.88 | PDE3A (0.77) | PDE3APDE4AHPGDBLMCYP3A4 | |
| SCHEMBL10512080 | 0.85 | PDE3A (0.74) | PDE3APDE4AHPGDBLMCYP3A4 | |
| SCHEMBL10514600 | 0.82 | PDE3A (0.70) | PDE3APDE4AHPGDBLMCYP3A4 | |
| SCHEMBL9460929 | 0.82 | PDE3A (0.70) | PDE3APDE4AHPGDBLMCYP3A4 | |
| SCHEMBL10573731 | 0.82 | PDE3A (0.69) | PDE3APDE4AHPGDBLMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117883374-B | Preparation method of olprinone hydrochloride injection composition | 芜湖杨燕制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119080769-A | Method for preparing olprinone hydrochloride | 芜湖御草医药有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-220949447-U | Dampproof device for storing olprinone intermediate | 湖南斯派克科技股份有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117883374-A | Preparation method of olprinone hydrochloride injection composition | 芜湖杨燕制药有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| CN-114773341-A | Preparation method of olprinone hydrochloride | 河北爱尔海泰制药有限公司 | 2022-07-22 | — | — | CN | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | claimed |
| US-6331543-B1 | TREATING SEXUAL DYSFUNCTION | NITROMED, INC. | 2001-12-18 | — | — | US | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| US-6172068-B1 | SEXUAL DISORDERS | NITROMED, INC. | 2001-01-09 | — | — | US | claimed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-0199127-B1 | 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative | Eisai Co., Ltd. (JP) | 1989-12-13 | — | — | EP | claimed |
| US-4751227-A | 3-cyano-5-(6-imidazo[1,2-a]pyridyl)pyridin-2-ols useful as cardiotonics | EISAI CO., LTD. (JP) | 1988-06-14 | — | — | US | claimed |
| EP-0199127-A1 | 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative | Eisai Co., Ltd. (JP) | 1986-10-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE3A 1/4885PDE4A 8/4885HPGD 396/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE3A 3/4885PDE4A 5/4885HPGD 597/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE3A 296/4885PDE4A 1073/4885HPGD 32/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE3A 296/4885PDE4A 1073/4885HPGD 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.